The risk of malignancy among biologic-naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database

Gu, Yun; Nordstrom, Beth L.

doi:10.1016/j.jaad.2017.03.044

Cited by 11 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our study did not identify a risk for lymphohematopoietic cancers, previous studies have reported a risk for their development in patients with psoriasis [6,20,[37][38][39][40]. Additionally, in a retrospective cohort study that included biologic-naive children with psoriasis and a control group of children without psoriasis, a risk for developing lymphoma was found only in the former [41]. Surprisingly, in our study no correlation was found between NMSC and psoriasis.…”

Section: Discussioncontrasting

confidence: 88%

Psoriasis—A Cancer Risk Factor?

et al. 2021

View full text Add to dashboard Cite

Psoriasis is not considered a strictly skin condition, but a complex disease with multisystem involvement due to the frequent associated comorbidities. We conducted a retrospective database study of 10,986 patients admitted in the interval January 2008–January 2019 to the Dermatology Clinic of the Iasi County “St. Spiridon” Emergency Hospital. Of the 10,986 patients admitted, 1288 were diagnosed with psoriasis. The association of malignancies was found in 40 of the psoriasis group cases and 399 of the control group cases that included various dermatological conditions. The calculation of Odds Ratios allowed us to determine if the patients with psoriasis could be at risk for certain malignancies. Thus, an association was suggested between psoriasis and central nervous system (CNS), upper aerodigestive tract cancer, endocrine cancer, bladder cancer, lung cancer, prostate cancer, breast cancer, or colorectal cancer. It is the first study of its kind in the northeastern region of Romania and can be the starting point for future long-term prospective cohort studies that will allow a more accurate data collection and a better understanding of the psoriasis–cancer relationship.

show abstract

Section: Discussioncontrasting

confidence: 88%

Psoriasis—A Cancer Risk Factor?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis conducted in 2013, the overall malignancy risk was elevated but consistent with previous studies (standard incidence ratio, SIR 1.16, 95% CI 1.07–1.25) with SIR 1.4 (95% CI 1.06–1.86) for non-Hodgkin lymphoma (NHL)[13]. A retrospective cohort study in biologic-naïve pediatric psoriasis patients found no significant increase in overall cancer risk compared to a matched pediatric population with no psoriasis, however increased lymphoma rate was observed when compared with the general population (SIR 5.42, 95% CI 1.62–12.94) [14]. Evidence for increase risk of solid tumors is inconsistent, but has been previously reported[11, 13, 12, 15] (Table 1).…”

Section: Baseline Risk Of Malignancy In Psoriasis Patientsmentioning

confidence: 99%

Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update

et al. 2017

View full text Add to dashboard Cite

Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.

show abstract

“…The pathogenesis of psoriasis is complex, and there are multiple risk factors including smoking, excessive alcohol intake, hypertension, hyperlipidemia, obesity and insulin resistance, which are in turn associated with cardiovascular disease (3). The majority of inflammatory cytokines, including tumor necrosis factor (TNF)-α and interferon-γ (IFN-γ), in psoriasis lesions and immune cells, including T helper cell type 1 (Th1) and Th17 in circulation, are increased in patients with psoriasis (4). A previous study demonstrated that psoriasis is associated with numerous types of comorbidities including metabolic syndrome (MS), diabetes, depression and cancer (5), thereby suggesting that psoriasis is an inflammatory and metabolic disease.…”

Section: Introductionmentioning

confidence: 99%

Abnormal expression of SIRTs in psoriasis: Decreased expression of SIRT 1-5 and increased expression of SIRT 6 and 7

et al. 2019

View full text Add to dashboard Cite

The prevalence of psoriasis is increasing, and poses a serious risk to human health and quality of life. Psoriasis, a chronic immune-mediated skin disease with epidermal hyperkeratosis and parakeratosis, is associated with numerous complications, including metabolic syndromes that are regulated by sirtuins (SIRTs) via deacetylation. As they serve a necessary function in inflammation and metabolism, SIRTs are considered to link inflammation and metabolic syndrome. Previous studies have indicated that SIRTs serve a function in the pathophysiology of psoriasis, but to date no detailed research has been conducted investigating the expression levels and patterns of SIRTs in psoriasis. The present study investigated the abnormal expression of SIRTs in psoriasis and provided a theoretical foundation for the treatment and prognosis of psoriasis. Tumor necrosis factor (TNF)-α-stimulated HaCaT cells and an imiquimod-induced psoriasis mouse model were used to produce in vitro and in vivo models, respectively. Psoriasis clinical specimens (psoriasis area and severity index >10; n=22) and normal group specimens (n=22) were obtained from human subjects. The mRNA and protein expression levels in human and mouse skin lesions and TNF-α-stimulated HaCaT cells were detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting, and compared with the control groups. The expression patterns of SIRT proteins were investigated using immunofluorescence (IF) staining. The expression levels of SIRT1, SIRT2, SIRT3, SIRT4 and SIRT5 were downregulated while those of SIRT6 and SIRT7 were upregulated in skin lesions and TNF-α-stimulated HaCaT cells compared with the control group as determined by RT-qPCR, western blotting and IF. Statistically significant differences were observed in vivo and in vitro . P-values of SIRT1-7 mRNA are less than 0.05 in RT-qPCR, and the P-values of SIRT1-7 proteins are less than 0.05 except for SIRT4 in the western blot analysis. SIRTs serve notable functions in severe psoriasis dermatitis, with the overexpression of SIRT6 and SIRT7 potentially induced by the adaptive immune response, and the downregulation of SIRT1, SIRT2, SIRT3, SIRT4 and SIRT5 may be a result of an internal environment imbalance in vivo . Psoriasis is an inflammation and metabolism-associated disease mediated by the SIRT family. The present results provide a novel potential mechanism and strategy for the treatment of psoriasis by modulating the function and expression of SIRTs.

show abstract

The risk of malignancy among biologic-naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database

Cited by 11 publications

References 30 publications

Psoriasis—A Cancer Risk Factor?

Psoriasis—A Cancer Risk Factor?

Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update

Abnormal expression of SIRTs in psoriasis: Decreased expression of SIRT 1-5 and increased expression of SIRT 6 and 7

Contact Info

Product

Resources

About